{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-000620","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.681998+00:00","generated_at":"2026-05-16T11:43:29.281500+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Structure Therapeutics licenses GLP-1 patents to Genentech for $100M upfront","bullets":["Gasherbrum Bio (Structure sub) grants non-exclusive license to Genentech/Roche for CT-996 GLP-1 RA.","Genentech pays $100M one-time non-refundable fee within 30 days; plus low single-digit royalties.","License covers patents distinct from aleniglipron; Structure's own GLP-1/dual agonist programs unaffected.","Either party may terminate for uncured material breach; Gasherbrum can terminate if GNE challenges patents."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-000620","json":"https://secwatch.observer/filing/0001104659-26-000620.json","markdown":"https://secwatch.observer/filing/0001104659-26-000620.md","text":"https://secwatch.observer/filing/0001104659-26-000620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/0001104659-26-000620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/tm261919d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:43:29.281500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1508cca0995f76fb59514eef093108b23e803cb2","claim":"Structure Therapeutics Inc. entered into GNE Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at $100 million (effective 2025-12-30).","evidence_excerpt":"On December 30, 2025, Gasherbrum Bio, Inc. (\"Gasherbrum\"), a wholly-owned subsidiary of Structure Therapeutics Inc. (the \"Company\"), entered into an agreement (the \"GNE Agreement\") with Genentech, Inc. (\"Genentech\") and F. Hoffmann-La Roche Ltd (\"Roche\" and together with Genentech, \"GNE\") that was the culmination of discussions initiated by Genentech’s inquiry regarding the availability of a license to certain patents of Gasherbrum","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/0001104659-26-000620-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Genentech, Inc. and F. Hoffmann-La Roche Ltd"},{"label":"Value","value":"$100 million"},{"label":"Effective","value":"2025-12-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}